urmjУральский медицинский журналUral Medical Journal2949-4389Ural State Medical University10.52420/umj.24.3.63SFJNRZurmj-1904Research ArticleОригинальные статьи | Original articlesOriginal articlesОценка безопасности и эффективности приема специализированного пищевого продукта у детей с ожирением 6-9 летAssessment of the Safety and Effectiveness of a Specialized Food Product in Obese Children Aged 6-9 Yearshttps://orcid.org/0000-0002-5250-7351КовтунО. П.KovtunO. P.

Ковтун Ольга Петровна — доктор медицинских наук, профессор, академик Российской академии наук, ректор.

Екатеринбург

Olga P. Kovtun — Doctor of Sciences (Medicine), Professor, Full Member (Academician) of the Russian Academy of Sciences, Rector, Ural State Medical University.

Ekaterinburg

usma@usma.ruhttps://orcid.org/0000-0002-4285-6902УстюжанинаМ. А.UstiuzhaninaM. A.

Устюжанина Маргарита Александровна — кандидат медицинских наук, доцент кафедры поликлинической педиатрии, институт педиатрии и репродуктивной медицины.

Екатеринбург

Margarita A. Ustiuzhanina — Candidate of Sciences (Medicine), Associate Professor of the Department of Polyclinic Pediatrics, Institute of Pediatrics and Reproductive Medicine, Ural State Medical University.

Ekaterinburg

ustmargarita@mail.ruhttps://orcid.org/0000-0002-2275-9347МайзельС. Г.MyzelS. G.

Майзель Сергей Гершевич — доктор технических наук, профессор, председатель совета директоров.

Екатеринбург

Sergey G. Myzel — Doctor of Sciences (Technology), Professor, Chairman of the Board of Directors, Pobeda-1 LLC.

Ekaterinburg

smayzel@gmail.comУральский государственный медицинский университетРоссияUral State Medical UniversityRussian FederationООО «Победа-1»РоссияPobeda-1 LLCRussian Federation20250607202524363–77Copyright © Ковтун О.П., Устюжанина М.А., Майзель С.Г., 20252025Ковтун О.П., Устюжанина М.А., Майзель С.Г.Kovtun O.P., Ustiuzhanina M.A., Myzel S.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.umjusmu.ru/jour/article/view/1904

Необходим поиск эффективных методов диетологических вмешательств с помощью специализированной пищевой продукции для снижения воспаления у детей с ожирением.

Цель исследования — оценить безопасность и эффективность приема специализированного пищевого продукта «Иммунокол ЛП» (лиофилизированная сыворотка молозива крупного рогатого скота) у детей 6–9 лет с ожирением.

Материалы и методы

Материалы и методы. Проведено одноцентровое проспективное экспериментальное исследование с участием 80 детей с ожирением (ИМТ >2,0 SDS по ВОЗ, 2009), распределенных в основную и контрольную группы (по 40 человек). Дети основной группы получали «Иммунокол ЛП» по одному саше (3 г) дважды в день за 30 мин. до еды курсом 28 дней. Оценивались: уровень C-реактивного белка (CРБ) и липополисахарида (ЛПС) в сыворотке крови, активность аланинаминотрансферазы (АЛТ), общий холестерин, показатели общего анализа крови (ОАК), уровень кальпротектина, концентрации короткоцепочечных жирных кислот (КЦЖК) в кале, состав микробиоты (ПЦР), антропометрия и биоимпедансный состав тела. Повторное обследование проводилось через 2 недели после завершения курса.

Результаты

Результаты. Прием «Иммунокола ЛП» сопровождался снижением CРБ в крови (p = 0,004), ЛПС (p = 0,002), АЛТ (p = 0,040), холестерина (p = 0,027), улучшением показателей ОАК. В кале отмечено повышение концентраций уксусной (p = 0,030) и пропионовой (p = 0,037) кислот. Видовой состав микробиоты не изменился. Динамика SDS ИМТ, роста и состава тела была сопоставимой в обеих группах.

Выводы

Выводы. Специализированный пищевой продукт «Иммунокол ЛП» продемонстрировал противовоспалительное действие, включая снижение системных маркеров воспаления (CРБ, ЛПС), снижение активности печеночного фермента АЛТ, улучшение показателей ОАК и активацию продукции КЦЖК в кишечнике. Продукт хорошо переносился и не вызывал нежелательных эффектов. С учетом полученных данных «Иммунокол ЛП» может рассматриваться в качестве дополнения к стандартной диетологической терапии у детей младшего возраста с ожирением.

Effective dietary interventions using specialized food products are needed to reduce inflammation in obese children. This study evaluated the safety and effectiveness of a lyophilized colostrum serum product, “Immunocol LP”, in children aged 6–9 years with obesity.

Materials and methods

Materials and methods. A prospective single-center study included 80 children (BMI >2.0 SDS by WHO, 2009), divided into a main group and a control group (n = 40 each). The main group received one sachet (3 g) of “Immunocol LP” twice daily, 30 min before meals for 28 days. The following were assessed: serum CRP, LPS, ALT, total cholesterol, CBC, fecal calprotectin, short-chain fatty acids (SCFA), microbiota composition (PCR), anthropometry, and body composition (bioimpedance). Follow-up was performed two weeks after treatment.

Results

Results. “Immunocol LP” intake led to a significant reduction in CRP (p = 0.004), LPS (p = 0.002), ALT (p = 0.040), and cholesterol (p = 0.027). Improvement in CBC and increased fecal SCFAs, including acetic (p = 0.030) and propionic acids (p = 0.037), were observed. Microbiota species composition remained unchanged. BMI, height, and body composition dynamics were similar in both groups.

Conclusion

Conclusion. “Immunocol LP” demonstrated anti-inflammatory effects by reducing systemic markers (CRP, LPS), lowering ALT, and stimulating SCFA production. It was well tolerated, with no adverse effects. These findings support the potential of “Immunocol LP” as an adjunct to dietary therapy in obese young children.

ожирениедетилокальное воспалениеметаболическое воспалениеИммуноколobesitychildrenlocal inflammationmeta-inflammationImmunocolReferencesSpinelli A, Buoncristiano M, Nardone P, Starc G, Hejgaard T, Júlíusson PB, et al. Thinness, overweight, and obesity in 6-to 9-year-old children from 36 countries: The World Health Organization European Childhood Obesity Surveillance Initiative-COSI 2015–2017. Obesity Reviews. 2021;22(Suppl 6):e13214. DOI: https://doi.org/10.1111/obr.13214.Spinelli A, Buoncristiano M, Nardone P, Starc G, Hejgaard T, Júlíusson PB, et al. Thinness, overweight, and obesity in 6-to 9-year-old children from 36 countries: The World Health Organization European Childhood Obesity Surveillance Initiative-COSI 2015–2017. Obesity Reviews. 2021;22(Suppl 6):e13214. DOI: https://doi.org/10.1111/obr.13214.Gates A, Elliott SA, Shulhan-Kilroy J, Ball GDC, Hartling L. Effectiveness and safety of interventions to manage childhood overweight and obesity: An Overview of Cochrane systematic reviews. Paediatrics & Child Health. 2021;26(5):310–316. DOI: https://doi.org/10.1093/pch/pxaa085.Gates A, Elliott SA, Shulhan-Kilroy J, Ball GDC, Hartling L. Effectiveness and safety of interventions to manage childhood overweight and obesity: An Overview of Cochrane systematic reviews. Paediatrics & Child Health. 2021;26(5):310–316. DOI: https://doi.org/10.1093/pch/pxaa085.Podchinenova DV, Samoilova YG, Kobyakova OS, Koshmeleva MV, Oleynik OA. Optimization of the algorithm for prevention and early diagnosis of metabolic syndrome and its predictors. Ural Medical Journal. 2019;(12):41–46. (In Russ.). EDN: https://www.elibrary.ru/LFBPVL.Podchinenova DV, Samoilova YG, Kobyakova OS, Koshmeleva MV, Oleynik OA. Optimization of the algorithm for prevention and early diagnosis of metabolic syndrome and its predictors. Ural Medical Journal. 2019;(12):41–46. (In Russ.). EDN: https://www.elibrary.ru/LFBPVL.Tarabrina AA, Samoilova YG, Oleynik OA, Matveeva MV, Subordenov DV, Diraeva NM, et al. Visceral obesity as a new area of research on mechanisms triggering allergic inflammation in children. Cardiovascular Therapy and Prevention. 2023;22(S6):32. (In Russ.). EDN: https://www.elibrary.ru/BGKXKD.Tarabrina AA, Samoilova YG, Oleynik OA, Matveeva MV, Subordenov DV, Diraeva NM, et al. Visceral obesity as a new area of research on mechanisms triggering allergic inflammation in children. Cardiovascular Therapy and Prevention. 2023;22(S6):32. (In Russ.). EDN: https://www.elibrary.ru/BGKXKD.Konishcheva AY, Lysogora VA, Gervazieva VB. The inflammatory patterns in patients with bronchial asthma and concomitant obesity. Russian Journal of Immunology. 2017;11(3):390–393. EDN: https://www.elibrary.ru/ZFXBJV.Konishcheva AY, Lysogora VA, Gervazieva VB. The inflammatory patterns in patients with bronchial asthma and concomitant obesity. Russian Journal of Immunology. 2017;11(3):390–393. EDN: https://www.elibrary.ru/ZFXBJV.Ferrante AW Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. Journal of Internal Medicine. 2007;262(4):408–414. DOI: https://doi.org/10.1111/j.1365-2796.2007.01852.x.Ferrante AW Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. Journal of Internal Medicine. 2007;262(4):408–414. DOI: https://doi.org/10.1111/j.1365-2796.2007.01852.x.Aboeldalyl S, James C, Seyam E, Ibrahim EM, Shawki HED, Amer S. The role of chronic inflammation in polycystic ovarian syndrome — a systematic review and meta-analysis. International Journal of Molecular Sciences. 2021;22(5):2734. DOI: https://doi.org/10.3390/ijms22052734.Aboeldalyl S, James C, Seyam E, Ibrahim EM, Shawki HED, Amer S. The role of chronic inflammation in polycystic ovarian syndrome — a systematic review and meta-analysis. International Journal of Molecular Sciences. 2021;22(5):2734. DOI: https://doi.org/10.3390/ijms22052734.Lainez NM, Coss D. Obesity, neuroinflammation, and reproductive function. Endocrinology. 2019; 160(11):2719–2736. DOI: https://doi.org/10.1210/en.2019-00487.Lainez NM, Coss D. Obesity, neuroinflammation, and reproductive function. Endocrinology. 2019; 160(11):2719–2736. DOI: https://doi.org/10.1210/en.2019-00487.Vetrani C, Di Nisio A, Paschou SA, Barrea L, Muscogiuri G, Graziadio C, et al. From gut microbiota through low-grade inflammation to obesity: Key players and potential targets. Nutrients. 2022;14(10):2103. DOI: https://doi.org/10.3390/nu14102103.Vetrani C, Di Nisio A, Paschou SA, Barrea L, Muscogiuri G, Graziadio C, et al. From gut microbiota through low-grade inflammation to obesity: Key players and potential targets. Nutrients. 2022;14(10):2103. DOI: https://doi.org/10.3390/nu14102103.Liébana-García R, Olivares M, Bullich-Vilarrubias C, López-Almela I, Romaní-Pérez M, Sanz Y. The gut microbiota as a versatile immunomodulator in obesity and associated metabolic disorders. Best Practice & Research Clinical Endocrinology & Metabolism. 2021;35(3):101542. DOI: https://doi.org/10.1016/j.beem.2021.101542.Liébana-García R, Olivares M, Bullich-Vilarrubias C, López-Almela I, Romaní-Pérez M, Sanz Y. The gut microbiota as a versatile immunomodulator in obesity and associated metabolic disorders. Best Practice & Research Clinical Endocrinology & Metabolism. 2021;35(3):101542. DOI: https://doi.org/10.1016/j.beem.2021.101542.Harris K, Kassis A, Major G, Chou CJ. Is the gut microbiota a new factor contributing to obesity and its metabolic disorders? Journal of Obesity. 2012;2012:879151. DOI: https://doi.org/10.1155/2012/879151.Harris K, Kassis A, Major G, Chou CJ. Is the gut microbiota a new factor contributing to obesity and its metabolic disorders? Journal of Obesity. 2012;2012:879151. DOI: https://doi.org/10.1155/2012/879151.Wang J, Chen WD, Wang YD. The relationship between gut microbiota and inflammatory diseases: The role of macrophages. Frontiers in Microbiology. 2020;11:1065. DOI: https://doi.org/10.3389/fmicb.2020.01065.Wang J, Chen WD, Wang YD. The relationship between gut microbiota and inflammatory diseases: The role of macrophages. Frontiers in Microbiology. 2020;11:1065. DOI: https://doi.org/10.3389/fmicb.2020.01065.Sun L, Ma L, Ma Y, Zhang F, Zhao C, Nie Y. Insights into the role of gut microbiota in obesity: Pathogenesis, mechanisms, and therapeutic perspectives. Protein & Cell. 2018;9(5):397–403. DOI: https://doi.org/10.1007/s13238-018-0546-3.Sun L, Ma L, Ma Y, Zhang F, Zhao C, Nie Y. Insights into the role of gut microbiota in obesity: Pathogenesis, mechanisms, and therapeutic perspectives. Protein & Cell. 2018;9(5):397–403. DOI: https://doi.org/10.1007/s13238-018-0546-3.Newman NK, Zhang Y, Padiadpu J, Miranda CL, Magana AA, Wong CP, et al. Reducing gut microbiome-driven adipose tissue inflammation alleviates metabolic syndrome. Microbiome. 2023;11(1):208. DOI: https://doi.org/10.1186/s40168-023-01637-4.Newman NK, Zhang Y, Padiadpu J, Miranda CL, Magana AA, Wong CP, et al. Reducing gut microbiome-driven adipose tissue inflammation alleviates metabolic syndrome. Microbiome. 2023;11(1):208. DOI: https://doi.org/10.1186/s40168-023-01637-4.ElSayed HL, Abdelsayed MGR, Emara ISA. Effect of lactoferrin supplementation on appetite and weight loss in obese school age children. QJM: An International Journal of Medicine. 2021;114(Suppl_1): hcab113.029. DOI: https://doi.org/10.1093/qjmed/hcab113.029.ElSayed HL, Abdelsayed MGR, Emara ISA. Effect of lactoferrin supplementation on appetite and weight loss in obese school age children. QJM: An International Journal of Medicine. 2021;114(Suppl_1): hcab113.029. DOI: https://doi.org/10.1093/qjmed/hcab113.029.Miyakawa M, Oda H, Tanaka M. Clinical research review: Usefulness of bovine lactoferrin in child health. BioMetals. 2023;36(3):473–489. DOI: https://doi.org/10.1007/s10534-022-00430-4.Miyakawa M, Oda H, Tanaka M. Clinical research review: Usefulness of bovine lactoferrin in child health. BioMetals. 2023;36(3):473–489. DOI: https://doi.org/10.1007/s10534-022-00430-4.de Onis M, Garza C, Victora CG, Onyango AW, Frongillo EA, Martines J. The WHO Multicentre Growth Reference Study: Planning, study design, and methodology. Food and Nutrition Bulletin. 2004;25(1 Suppl): S15–S26. DOI: https://doi.org/10.1177/15648265040251S104.de Onis M, Garza C, Victora CG, Onyango AW, Frongillo EA, Martines J. The WHO Multicentre Growth Reference Study: Planning, study design, and methodology. Food and Nutrition Bulletin. 2004;25(1 Suppl): S15–S26. DOI: https://doi.org/10.1177/15648265040251S104.Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: A lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cellular and Molecular Life Sciences. 2005;62(22):2588–2598. DOI: https://doi.org/10.1007/s00018-005-5373-z.Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: A lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cellular and Molecular Life Sciences. 2005;62(22):2588–2598. DOI: https://doi.org/10.1007/s00018-005-5373-z.Zhang L, Rozek A, Hancock REW. Interaction of cationic antimicrobial peptides with model membranes. The Journal of Biological Chemistry. 2001;276(38):35714–35722. DOI: https://doi.org/10.1074/jbc.M104925200.Zhang L, Rozek A, Hancock REW. Interaction of cationic antimicrobial peptides with model membranes. The Journal of Biological Chemistry. 2001;276(38):35714–35722. DOI: https://doi.org/10.1074/jbc.M104925200.Drago-Serrano ME, De La Garza-Amaya M, Luna JS, Campos-Rodríguez R. Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects. International Immunopharmacology. 2012; 12(1):1–9. DOI: https://doi.org/10.1016/j.intimp.2011.11.002.Drago-Serrano ME, De La Garza-Amaya M, Luna JS, Campos-Rodríguez R. Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects. International Immunopharmacology. 2012; 12(1):1–9. DOI: https://doi.org/10.1016/j.intimp.2011.11.002.Connell S, Kawashima M, Nakamura S, Imada T, Yamamoto H, Tsubota K, et al. Lactoferrin ameliorates dry eye disease potentially through enhancement of short-chain fatty acid production by gut microbiota in mice. International Journal of Molecular Sciences. 2021;22(22):12384. DOI: https://doi.org/10.3390/ijms222212384.Connell S, Kawashima M, Nakamura S, Imada T, Yamamoto H, Tsubota K, et al. Lactoferrin ameliorates dry eye disease potentially through enhancement of short-chain fatty acid production by gut microbiota in mice. International Journal of Molecular Sciences. 2021;22(22):12384. DOI: https://doi.org/10.3390/ijms222212384.Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’Amato M, et al. Intestinal barrier and permeability in health, obesity and NAFLD. Biomedicines. 2021;10(1):83. DOI: https://doi.org/10.3390/biomedicines10010083.Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’Amato M, et al. Intestinal barrier and permeability in health, obesity and NAFLD. Biomedicines. 2021;10(1):83. DOI: https://doi.org/10.3390/biomedicines10010083.Hartman C, Rennert HS, Rennert G, Elenberg Y, Zuckerman E. Prevalence of elevated liver enzymes and comorbidities in children and adolescents with overweight and obesity. Acta Paediatrica. 2021;110(3):985–992. DOI: https://doi.org/10.1111/apa.15469.Hartman C, Rennert HS, Rennert G, Elenberg Y, Zuckerman E. Prevalence of elevated liver enzymes and comorbidities in children and adolescents with overweight and obesity. Acta Paediatrica. 2021;110(3):985–992. DOI: https://doi.org/10.1111/apa.15469.Valle-Martos R, Jiménez-Reina L, Cañete R, Martos R, Valle M, Cañete MD. Changes in liver enzymes are associated with changes in insulin resistance, inflammatory biomarkers and leptin in prepubertal children with obesity. Italian Journal of Pediatrics. 2023;49(1):29. DOI: https://doi.org/10.1186/s13052-023-01434-7.Valle-Martos R, Jiménez-Reina L, Cañete R, Martos R, Valle M, Cañete MD. Changes in liver enzymes are associated with changes in insulin resistance, inflammatory biomarkers and leptin in prepubertal children with obesity. Italian Journal of Pediatrics. 2023;49(1):29. DOI: https://doi.org/10.1186/s13052-023-01434-7.Nixdorf L, Hartl L, Ströhl S, Felsenreich DM, Mairinger M, Jedamzik J, et al. Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: A prospective study. Scientific Reports. 2024; 14(1):17558. DOI: https://doi.org/10.1038/s41598-024-67415-w.Nixdorf L, Hartl L, Ströhl S, Felsenreich DM, Mairinger M, Jedamzik J, et al. Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: A prospective study. Scientific Reports. 2024; 14(1):17558. DOI: https://doi.org/10.1038/s41598-024-67415-w.

The authors declare that there are no conflicts of interest present.